BH_NonClinical_Pharmacy_Car-T
Details
| Contract Title: | BH_NonClinical_Pharmacy_Car-T |
| Published Date: | Nov 27, 2025 |
| Notice Type: | Award (ContractAwardNotice) |
| Value Banding: | High Value |
| Delivery Point: | United Kingdom |
Description:
CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells. The proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products At the time of writing it is only offered at 8 sites across the UK. The proposed contract is for 5 years with the option to extend by up to a further 5 years. The contract does not commit the Trust to place a minimum or any Ord...